Male Hypogonadism

1. Overview
2. Classification: Primary vs Secondary
3. Epidemiology
4. Causes and Risk Factors
5. Clinical Presentation
6. Diagnosis and Laboratory Evaluation
7. Testosterone Replacement Therapy
8. Monitoring and Complications of TRT
9. Special Populations
10. Key Research Papers
11. Connections
12. Featured Videos

Overview

Male hypogonadism is the failure of the testes to produce sufficient testosterone and/or sperm. Testosterone is the primary male androgen — the hormone responsible for the development of male reproductive organs, secondary sex characteristics, muscle mass, bone density, mood, and energy. It is synthesized in the Leydig cells of the testes under stimulation from the pituitary hormone LH (luteinizing hormone).

The normal serum testosterone range is approximately 300–1,000 ng/dL, though reference ranges vary by laboratory and assay method. After age 30, testosterone declines at roughly 1–2% per year — a gradual but clinically meaningful drop over decades.

The regulatory pathway governing testosterone production is the hypothalamic-pituitary-gonadal (HPG) axis: the hypothalamus releases GnRH (gonadotropin-releasing hormone) in pulses, which signals the pituitary gland to release LH and FSH (follicle-stimulating hormone). LH drives testosterone production in the Leydig cells; FSH supports sperm production in the Sertoli cells. Disruption at any point along this axis — hypothalamus, pituitary, or testis — can cause hypogonadism.

An estimated 4–5 million men in the United States have been diagnosed with hypogonadism, though many more remain undiagnosed because symptoms such as fatigue, low libido, and depression are often attributed to other causes or dismissed as normal aging.

Back to Table of Contents

Classification: Primary vs Secondary Hypogonadism

Hypogonadism is classified by where the fault lies in the HPG axis. This distinction is clinically essential because it determines the underlying cause, the hormonal picture, and — critically — the correct treatment strategy (especially for men who want to preserve fertility).

Primary Hypogonadism (Hypergonadotropic)

In primary hypogonadism, the testes themselves fail to respond adequately to hormonal signals. The pituitary compensates by releasing more LH and FSH in an attempt to stimulate the unresponsive testes. The characteristic lab pattern is: low testosterone + high LH and FSH.

FSH is specifically elevated when spermatogenesis (sperm production) is impaired, because FSH drives sperm production via the Sertoli cells. High FSH with low sperm count is a hallmark of primary testicular failure.

Common causes of primary hypogonadism include:

• Klinefelter syndrome (47,XXY) — the most common genetic cause; affects 1 in 500–1,000 males; the extra X chromosome interferes with testicular development; testes are typically small and firm; men often have tall stature, gynecomastia, and infertility
• Cryptorchidism — undescended testes; if uncorrected, the elevated scrotal temperature damages Leydig and Sertoli cells over time
• Orchitis — testicular inflammation; mumps orchitis in postpubertal males is a well-known cause of primary hypogonadism
• Chemotherapy and radiation therapy — alkylating agents (cyclophosphamide, busulfan) and pelvic/gonadal radiation are highly gonadotoxic
• Testicular torsion — loss of blood supply; if not rapidly corrected, can cause permanent testicular damage
• Trauma to the testes
• Autoimmune orchitis — rare; antibodies target testicular tissue
• Varicocele — abnormal dilation of scrotal veins; elevates intrascrotal temperature; a reversible cause of both subfertility and low testosterone in some men

Secondary Hypogonadism (Hypogonadotropic)

In secondary hypogonadism, the testes are structurally normal but receive insufficient hormonal stimulation because the hypothalamus or pituitary is not functioning correctly. The lab pattern is: low testosterone + low or inappropriately normal LH and FSH.

Common causes of secondary hypogonadism include:

• Kallmann syndrome — congenital GnRH deficiency combined with anosmia (absent sense of smell); caused by failure of GnRH neurons to migrate from the olfactory bulb to the hypothalamus during fetal development; results in absent puberty if untreated
• Pituitary adenoma — prolactinoma (prolactin-secreting tumor) is the most common pituitary tumor causing hypogonadism; high prolactin suppresses GnRH release; other pituitary tumors can compress the gonadotrope cells
• Hemochromatosis — iron deposits in the pituitary selectively damage gonadotrope cells, causing secondary hypogonadism; often the first endocrine manifestation of hereditary hemochromatosis
• Obesity — excess adipose tissue contains high levels of the enzyme aromatase, which converts testosterone to estradiol; elevated estradiol feeds back to suppress GnRH and LH release from the hypothalamus and pituitary; the result is a functional, reversible secondary hypogonadism that can improve substantially with weight loss
• Opioid use — opioids bind mu-opioid receptors in the hypothalamus and directly suppress GnRH pulsatility, causing secondary hypogonadism in 70–90% of men on chronic opioids
• Glucocorticoids — chronic steroid use suppresses GnRH and LH secretion
• Anabolic steroid use/abuse — exogenous androgens shut down the HPG axis via negative feedback; after stopping, recovery can take months to years and is sometimes incomplete
• Idiopathic hypogonadotropic hypogonadism (IHH) — congenital GnRH deficiency without anosmia
• Systemic illness — critical illness, HIV/AIDS, cirrhosis, chronic kidney disease, and malnutrition can all suppress the HPG axis

Mixed/Combined Hypogonadism

In late-onset hypogonadism (LOH) — the age-related form — both the testes and the HPG axis contribute to testosterone decline. Aging reduces both Leydig cell mass and the amplitude of LH pulses. This explains why older men may have only modestly elevated (rather than markedly elevated) LH even when testosterone is substantially below normal.

Back to Table of Contents

Epidemiology

Male hypogonadism is far more prevalent than commonly recognized. Biochemical low testosterone (below 300 ng/dL) increases sharply with age:

• Approximately 20% of men over age 60 have low testosterone by biochemical criteria
• Approximately 30% of men over age 70
• Approximately 50% of men over age 80

However, many older men with low testosterone are asymptomatic, and biochemical hypogonadism alone is not sufficient to diagnose symptomatic hypogonadism requiring treatment.

Obesity is the single strongest modifiable risk factor. Adipose tissue aromatase activity rises with body fat, increasing estradiol and suppressing LH. Obese men are 2–3 times more likely to have low testosterone than lean men, and the effect is dose-dependent with BMI. Weight loss of 10% or more can meaningfully raise testosterone levels without any pharmacological treatment.

Type 2 diabetes is associated with a 2-fold higher prevalence of hypogonadism compared to the general population. The mechanism involves both insulin resistance affecting Leydig cell function and obesity-driven HPG suppression. The relationship is bidirectional — low testosterone also worsens insulin resistance and metabolic syndrome.

Opioid-induced hypogonadism (OPIH) is a largely underappreciated epidemic: 70–90% of men on chronic opioid therapy develop biochemical hypogonadism, yet this is rarely screened for or treated in pain management settings. The onset can occur within weeks of starting high-dose opioids.

Back to Table of Contents

Causes and Risk Factors

Causes vary by the type of hypogonadism (primary vs secondary) and the age of onset. Key risk factors and contributing conditions include:

• Age over 40 — the most common risk factor for late-onset hypogonadism
• Obesity (BMI >30) — increases aromatase activity and suppresses the HPG axis
• Type 2 diabetes and metabolic syndrome — strongly associated; often coexist with and worsen low testosterone
• Chronic opioid use — codeine, oxycodone, hydrocodone, morphine, fentanyl, methadone; all suppress GnRH
• Anabolic steroid use — current or past; HPG suppression may be prolonged after discontinuation
• Pituitary or hypothalamic disease — tumors, surgery, radiation, infiltrative disease (sarcoidosis, histiocytosis X)
• Hemochromatosis — iron overload; hypogonadism may be the presenting sign
• Prior chemotherapy or radiation to the pelvis/gonads
• Testicular injury or torsion
• HIV/AIDS — hypogonadism occurs in 20–50% of men with HIV, via both primary and secondary mechanisms
• Chronic kidney disease or dialysis
• Liver cirrhosis — reduces testosterone production and increases SHBG
• Glucocorticoid therapy (prednisone, dexamethasone) — suppresses LH and testosterone production
• Genetic causes — Klinefelter syndrome (47,XXY), Kallmann syndrome, Y-chromosome microdeletions affecting spermatogenesis
• Sleep apnea — severe untreated obstructive sleep apnea reduces nocturnal testosterone peaks; treatment of sleep apnea can improve testosterone levels

Back to Table of Contents

Clinical Presentation

The symptoms of male hypogonadism depend on the age of onset (before or after puberty) and the degree of testosterone deficiency. Symptoms are non-specific, overlap with many other conditions, and are often dismissed — which contributes to delayed diagnosis.

Sexual Symptoms

• Decreased libido — the most consistent and commonly reported symptom; often the first sign patients notice
• Erectile dysfunction — particularly loss of spontaneous and morning erections; testosterone does not cause erections per se, but it maintains the neurological and vascular sensitivity needed for sexual response
• Decreased morning erections — morning erections (nocturnal penile tumescence) are a useful clinical sign; their loss often correlates with low testosterone
• Reduced semen volume
• Infertility — impaired spermatogenesis; FSH elevation in primary hypogonadism signals Sertoli cell failure

Physical Symptoms

• Decreased muscle mass and strength — testosterone is an anabolic hormone; deficiency leads to progressive sarcopenia
• Increased body fat — particularly visceral (abdominal) fat; creates a vicious cycle as visceral fat aromatizes more testosterone to estradiol
• Decreased bone mineral density — testosterone is essential for maintaining bone mass in men; prolonged deficiency causes osteoporosis and increases fracture risk
• Decreased body and facial hair — reduced androgen-dependent hair growth
• Gynecomastia — breast tissue development; occurs especially when the testosterone-to-estradiol ratio is low; more common in primary hypogonadism and obesity-related cases
• Small or soft testes — a hallmark of primary hypogonadism; testicular volume below 15 mL in adults is abnormal
• Loss of height — vertebral compression fractures from osteoporosis
• Hot flashes — less common than in women but reported in men with abrupt testosterone withdrawal (e.g., after androgen deprivation therapy for prostate cancer)

Neuropsychiatric Symptoms

• Fatigue and low energy
• Depression and low mood
• Irritability and mood instability
• Decreased motivation and drive
• "Brain fog" — poor concentration, slowed cognitive processing, word-finding difficulty
• Sleep disturbances — difficulty initiating or maintaining sleep

Metabolic Symptoms

• Insulin resistance and elevated blood glucose
• Features of metabolic syndrome — central obesity, hypertriglyceridemia, low HDL cholesterol, hypertension
• Anemia — testosterone stimulates erythropoietin and red blood cell production; deficiency can cause a mild normocytic anemia

Pre-pubertal vs Post-pubertal Onset

If hypogonadism begins before puberty (congenital or childhood-onset), the physical features are more dramatic:

• Micropenis — impaired androgen-driven growth of the penis in infancy
• Undescended or small testes
• Delayed or absent puberty — no voice deepening, sparse pubic/axillary hair, no growth spurt
• Eunuchoid body proportions — arm span exceeds height by more than 5 cm; legs are disproportionately long; occurs because the long-bone growth plates (epiphyses) stay open longer without testosterone to close them
• High-pitched voice
• Absent or minimal ejaculate

Back to Table of Contents

Diagnosis and Laboratory Evaluation

Diagnosis requires both biochemical confirmation of low testosterone and clinical symptoms consistent with hypogonadism. Biochemical low testosterone alone, without symptoms, does not automatically require treatment. The evaluation follows a logical sequence designed to confirm the diagnosis, determine the cause, and identify any treatable underlying conditions.

Total Testosterone

The initial and most important test. Key points for accurate measurement:

• Draw a morning fasting sample between 8–10 am; testosterone peaks in the early morning due to circadian pulsatility and may be 20–30% higher than afternoon values
• Confirm on two separate mornings before diagnosing hypogonadism; single measurements can be unreliable
• The threshold for considering treatment is typically below 300 ng/dL in the presence of symptoms, though guidelines vary slightly and clinical judgment is essential
• Use a liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay when possible — it is more accurate than older immunoassay methods, especially at low testosterone concentrations

Free Testosterone

Only about 2% of total testosterone is "free" (unbound, biologically active). The rest is bound to sex hormone-binding globulin (SHBG; ~60%) and albumin (~38%). SHBG-bound testosterone is generally not bioavailable; albumin-bound testosterone is loosely bound and partially available to tissues.

Free testosterone measurement or calculation is important when:

• Obesity — lowers SHBG, so total T may look normal but free T can be relatively preserved; less often a problem but check when total T is borderline
• Aging or liver disease — raises SHBG, so total T appears higher than the biologically active fraction; a man may have a normal total T but very low free T
• Conditions affecting SHBG (see below)

Free testosterone is best measured by equilibrium dialysis (gold standard) or calculated using the Vermeulen formula (requires SHBG and albumin levels). Direct free testosterone immunoassays are generally unreliable.

LH and FSH

These are the most diagnostically important tests after confirming low testosterone. They must be ordered before starting testosterone replacement therapy — exogenous testosterone suppresses LH production, making it impossible to distinguish primary from secondary hypogonadism after treatment has begun.

• High LH + high FSH + low T = primary hypogonadism (testicular failure)
• Low or normal LH + low or normal FSH + low T = secondary hypogonadism (pituitary or hypothalamic cause)

Elevated FSH specifically indicates impaired spermatogenesis (Sertoli cell failure) and predicts poorer fertility outcomes.

Prolactin

Should be measured in all cases of secondary hypogonadism (low LH/FSH). An elevated prolactin level raises suspicion for a prolactinoma (prolactin-secreting pituitary adenoma), the most common pituitary tumor. High prolactin suppresses GnRH pulsatility. Treatment of prolactinoma with dopamine agonists (cabergoline, bromocriptine) often restores testosterone without requiring TRT.

SHBG (Sex Hormone-Binding Globulin)

SHBG is elevated in: aging, liver disease (hepatitis, cirrhosis), hyperthyroidism, HIV, and use of anticonvulsants. SHBG is reduced in: obesity, hypothyroidism, type 2 diabetes, glucocorticoid use, and nephrotic syndrome. Knowing SHBG allows calculation of free testosterone and helps interpret total testosterone results.

Estradiol (E2)

Important to measure if gynecomastia is present or if there is clinical suspicion of estrogen excess. Aromatase in adipose tissue converts testosterone to estradiol; obesity and liver disease can elevate estradiol and suppress LH. High estradiol with low testosterone may indicate obesity-driven functional hypogonadism that responds primarily to weight loss.

Complete Blood Count (CBC)

Baseline hematocrit is essential before starting TRT. Testosterone stimulates red blood cell production; erythrocytosis (high hematocrit) is one of the most common side effects of TRT. TRT is contraindicated if the baseline hematocrit exceeds 54% due to increased thrombosis risk.

Bone Density (DXA Scan)

Recommended in men who have had hypogonadism for more than one year, men with a history of minimal-trauma fractures, or men with symptoms of vertebral compression. Testosterone is a key regulator of bone turnover in men; prolonged deficiency causes osteoporosis that may not be clinically apparent until a fracture occurs.

Karyotype

Indicated in men with primary hypogonadism to exclude Klinefelter syndrome (47,XXY). Klinefelter is frequently undiagnosed until men present with infertility or in middle age with classic findings (small firm testes, gynecomastia, tall stature, learning differences).

Iron Studies and Ferritin

Screen for hemochromatosis in secondary hypogonadism — serum ferritin and transferrin saturation. Hemochromatosis causes iron deposition in the pituitary gland and selectively damages gonadotrope cells, producing a characteristic secondary hypogonadism. Treating the iron overload (phlebotomy) can partially restore pituitary function.

MRI of the Pituitary

Required when secondary hypogonadism is confirmed (low LH/FSH) — especially if prolactin is elevated or total testosterone is very low (<150 ng/dL). MRI can detect pituitary adenomas, other pituitary masses, the empty sella syndrome, and structural hypothalamic abnormalities.

Semen Analysis

Essential if the patient desires fertility. Provides direct information about spermatogenesis. A man with low testosterone and azoospermia (no sperm) or severe oligospermia has a different treatment pathway than a man with low testosterone and normal sperm count.

Back to Table of Contents

Testosterone Replacement Therapy

Testosterone replacement therapy (TRT) is the standard treatment for symptomatic hypogonadism in men who do not wish to preserve fertility. The goal is to restore testosterone to the mid-normal physiological range (~400–700 ng/dL), relieve symptoms, and prevent long-term complications such as bone loss and metabolic deterioration.

Multiple formulations are available, each with different pharmacokinetics, convenience, cost, and side-effect profiles. Shared decision-making between patient and clinician is essential.

Intramuscular Injections

Testosterone cypionate and testosterone enanthate are the most widely used injectable formulations in the United States. They are administered at 100–200 mg IM every 1–2 weeks. These produce a supraphysiologic peak in the first 2–3 days after injection, followed by a gradual decline toward trough levels before the next dose — creating a "roller coaster" pattern that some men experience as mood or energy fluctuations.

Testosterone undecanoate (Aveed) is a long-acting injectable given at 750 mg IM at weeks 0 and 4, then every 10 weeks. It produces more stable levels and requires fewer injections, but carries a rare risk of pulmonary oil microembolism and must be administered in a healthcare setting. Injections are the least expensive TRT formulation.

Transdermal Gels

Testosterone gels (1.62% or 2%; brand names include AndroGel, Testim, Vogelxo) are applied daily to the shoulders, upper arms, or abdomen. They produce relatively steady-state testosterone levels and are the most commonly prescribed TRT formulation in the United States. Key considerations:

• Transfer risk — gel can transfer to female partners and children through skin contact, potentially causing virilization; men must cover application sites, wash hands thoroughly, and women and children should avoid touching treated skin
• Absorption varies among individuals; some men require dose adjustments to reach target levels
• More expensive than injections; generic versions are available

Transdermal Patch

Androderm is applied nightly to non-scrotal skin and releases testosterone over 24 hours. Skin irritation and erythema at the application site are common and are the leading reason men discontinue the patch.

Buccal System

Striant is a buccal adhesive tablet applied to the gum above the upper incisors twice daily. It releases testosterone via the buccal mucosa. Gum irritation, altered taste, and the need for twice-daily application limit its use.

Subcutaneous Pellets

Testopel pellets are implanted subcutaneously (usually in the buttocks or hip) every 3–6 months under local anesthesia. They provide the most stable, physiologically consistent testosterone levels of any formulation — no daily administration required. The minor surgical procedure carries small risks of pellet extrusion, infection, or fibrosis at the implant site.

Nasal Gel

Natesto is a testosterone gel delivered intranasally three times daily. Its unique advantage is that it produces shorter duration of testosterone elevation, which results in less suppression of the HPG axis compared to other formulations. This makes it potentially useful in men who wish to maintain some degree of spermatogenesis while treating symptomatic hypogonadism.

Oral Testosterone

Testosterone undecanoate (Tlando, Kyzaleo) received FDA approval in 2022 as a twice-daily oral capsule taken with food. It is absorbed via intestinal lymphatic vessels, bypassing first-pass hepatic metabolism — unlike older oral methyltestosterone, which was hepatotoxic. Oral administration offers convenience but testosterone levels can be more variable than with transdermal or injectable formulations.

Contraindications to TRT

TRT should not be initiated in men with any of the following:

• Prostate cancer (active or suspected) — testosterone drives prostate cancer growth; this is an absolute contraindication
• Male breast cancer
• Erythrocytosis — hematocrit above 54%; testosterone further increases red blood cell mass and raises thrombosis risk
• Severe untreated obstructive sleep apnea — TRT can worsen sleep apnea by reducing respiratory drive; apnea should be treated before or alongside TRT
• Uncontrolled heart failure
• Desire for fertility in the near term — exogenous testosterone suppresses LH and FSH, which shuts down spermatogenesis; men who want children should use fertility-preserving alternatives (see Special Populations section)
• Active venous thromboembolism

Back to Table of Contents

Monitoring and Complications of TRT

TRT requires structured follow-up to ensure therapeutic benefit, detect side effects early, and rule out rare but serious complications. Initial monitoring is typically at 3 and 6 months after starting therapy, then annually once levels are stable.

Total Testosterone Level

Target the mid-normal physiological range: approximately 400–700 ng/dL. Testing timing depends on the formulation:

• Injections (cypionate/enanthate): check midway between injections (the "trough-to-peak midpoint")
• Gels: check 2–8 hours after application
• Oral (undecanoate): check 3–5 hours after the morning dose
• Pellets: check 4–6 weeks after implantation

Hematocrit (Erythrocytosis)

The most common clinically important side effect of TRT. Testosterone stimulates erythropoietin production and directly stimulates bone marrow red cell production. Hematocrit should be checked at baseline and at each follow-up visit. If hematocrit rises above 54%:

• Reduce the TRT dose or switch to a lower-dose formulation
• Perform therapeutic phlebotomy if needed
• Investigate for secondary causes (sleep apnea, polycythemia vera)
• High hematocrit increases blood viscosity and raises risk of deep vein thrombosis and stroke

PSA (Prostate-Specific Antigen)

TRT raises PSA, which reflects normal prostate growth under androgenic stimulation rather than necessarily indicating cancer. However, monitoring is essential:

• Measure PSA at baseline before starting TRT
• Recheck at 3–6 months after initiation, then annually
• A rise of more than 1.4 ng/mL above baseline within the first year warrants urology referral
• Do NOT start TRT if baseline PSA is above 4 ng/mL or if digital rectal examination (DRE) is suspicious for prostate cancer without prior urology evaluation

Estradiol

Some men on TRT develop elevated estradiol due to peripheral aromatization — particularly those who are obese. Symptoms of excess estrogen include gynecomastia, water retention, mood changes, and nipple sensitivity. If symptomatic, estradiol can be measured and aromatase inhibitors (anastrozole, exemestane) considered, though routine use of aromatase inhibitors with TRT is generally not recommended without clear indication.

Bone Mineral Density

Repeat DXA scan 1–2 years after achieving stable normal testosterone levels in men with pre-treatment osteopenia or osteoporosis. TRT consistently improves bone mineral density in hypogonadal men and can reduce vertebral fracture risk over time.

Cardiovascular Monitoring

The cardiovascular effects of TRT have been debated for over a decade. The landmark TRAVERSE trial (2023) demonstrated that testosterone therapy was non-inferior to placebo for major adverse cardiovascular events (MACE — heart attack, stroke, cardiovascular death) in men with hypogonadism and pre-existing high cardiovascular risk. This provided important reassurance about TRT safety in typical clinical populations. However, the erythrocytosis risk remains a real cardiovascular concern and must be monitored.

Fertility and HPG Suppression

Men on TRT should understand that exogenous testosterone suppresses their own testosterone production and spermatogenesis through HPG axis feedback. Testicular atrophy (shrinkage) can occur over time. Men who later wish to have children may need to discontinue TRT and use fertility treatments (see Special Populations) — recovery of spermatogenesis is not guaranteed and can be slow.

Back to Table of Contents

Special Populations

Men Who Want to Preserve Fertility

Exogenous testosterone replacement is the wrong treatment for a hypogonadal man who wants to father children. By suppressing LH and FSH, TRT shuts down intratesticular testosterone production and spermatogenesis. Fertility-preserving alternatives include:

• Clomiphene citrate (clomid) — a selective estrogen receptor modulator (SERM) that blocks estrogen feedback at the hypothalamus and pituitary, thereby increasing GnRH and LH/FSH pulsatility; this stimulates the testes to produce both testosterone and sperm; taken orally; highly effective for secondary hypogonadism; does not suppress the HPG axis
• Human chorionic gonadotropin (hCG) — an LH analog; injected subcutaneously 2–3 times per week; directly stimulates Leydig cells to produce testosterone and maintains testicular volume and spermatogenesis; often combined with FSH injections in men with pituitary failure; more expensive than clomiphene but highly effective
• Recombinant FSH injections — specifically needed for spermatogenesis in men with secondary hypogonadism due to pituitary failure (FSH is the direct driver of Sertoli cell activity and sperm production)
• Nasal testosterone gel (Natesto) — as noted, produces less HPG suppression than other TRT formulations and may preserve some spermatogenesis, though it is less studied in this role

Opioid-Induced Hypogonadism (OPIH)

Opioid-induced hypogonadism is one of the most common yet underdiagnosed forms of secondary hypogonadism in men. Opioids bind to mu-opioid receptors in the hypothalamus and directly suppress the pulsatile release of GnRH. This cascade reduces LH and FSH secretion and leads to low intratesticular testosterone and impaired spermatogenesis.

The prevalence is striking: 70–90% of men on chronic opioid therapy develop biochemical hypogonadism, and onset can occur within weeks of starting high-dose opioids. All opioids carry this risk — including opioid agonist therapies such as methadone and buprenorphine used for opioid use disorder.

Clinical management of OPIH:

• Screen all men on chronic opioids with morning testosterone + LH/FSH
• The ideal management is dose reduction or tapering of opioids where medically feasible — testosterone often recovers partially or fully
• TRT is appropriate in men with symptomatic hypogonadism whose opioid dose cannot be reduced and who do not need fertility preservation; monitor closely for erythrocytosis
• Clomiphene can be tried in OPIH but is less reliably effective because the primary lesion is hypothalamic GnRH suppression rather than pituitary failure

Late-Onset Hypogonadism (Age-Related)

Age-related testosterone decline is real but not universal. Some men maintain testosterone in the normal range into their 80s; others fall below 300 ng/dL by their 50s. Factors that accelerate the decline include obesity, diabetes, chronic illness, and sedentary lifestyle.

The Testosterone Trials (TTrials) were a landmark set of 7 coordinated randomized controlled trials conducted in 788 men aged 65 and older with serum testosterone below 275 ng/dL. Results (published 2016 in NEJM) showed that TRT over one year significantly improved:

• Sexual function and activity (most consistent benefit)
• Walking distance and physical function (modest improvement in men with mobility limitations)
• Hemoglobin (correction of anemia of hypogonadism)
• Bone mineral density (significant increase at the spine and hip)

The TTrials found no evidence of increased cardiovascular events in this short-term study, and the TRAVERSE trial (2023) subsequently confirmed cardiovascular safety in a larger, longer-term population. The TTrials did not demonstrate consistent improvement in cognitive function or mood as primary endpoints, though secondary analyses suggested some benefit.

Cardiovascular Disease and the TRAVERSE Trial

For over a decade, concern about cardiovascular safety was one of the primary barriers to TRT use, stemming from two small observational studies in 2010 and 2013. The FDA added a cardiovascular risk warning to testosterone product labels in 2015. The TRAVERSE trial (Lincoff et al., NEJM 2023) was a large (5,246 participants), randomized, double-blind trial designed specifically to address this question. Men with hypogonadism and either existing cardiovascular disease or high cardiovascular risk were randomized to testosterone gel vs placebo for up to 4 years. The result: testosterone therapy was non-inferior to placebo for MACE (composite of death, heart attack, or stroke). This trial has substantially changed the risk-benefit discussion around TRT in men with cardiovascular disease.

Back to Table of Contents

Key Research Papers

1. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715–1744. PMID 29562364
2. Bhasin S, Pencina M, Jasuja GK, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men. J Clin Endocrinol Metab. 2011;96(8):2430–2439. PMID 21646370
3. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611–624. PMID 26886521
4. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389(2):107–117. PMID 37154370
5. Nieschlag E, Nieschlag S, Behre HM. Testosterone deficiency: a historical perspective. Asian J Androl. 2015;17(1):3–6. PMID 25652625
6. Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract. 2010;64(6):682–696. PMID 20002898
7. Finkelstein JS, Lee H, Burnett-Bowie SA, et al. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013;369(11):1011–1022. PMID 24224659
8. Saad F, Gooren L, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl. 2005;26(3):352–358. PMID 15835705
9. Hackett G, Kirby M, Edwards D, et al. British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, with Statements for UK Practice. J Sex Med. 2017;14(12):1504–1523. PMID 28873536
10. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63(3):280–293. PMID 16181231
11. Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99–R116. PMID 26537862
12. Buvat J, Maggi M, Guay A, Torres LO. Testosterone deficiency in men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med. 2013;10(1):245–284. PMID 23480785

Back to Table of Contents

Connections

• Endocrinology Conditions
• Hypopituitarism — secondary hypogonadism from pituitary failure
• Prolactinoma — most common pituitary tumor causing hypogonadism
• Metabolic Syndrome — strongly associated with low testosterone
• Osteoporosis — testosterone deficiency causes significant bone loss in men
• Diabetes — low testosterone doubles metabolic risk; bidirectional relationship
• Zinc — essential mineral for testosterone synthesis and testicular function
• Amino Acids — protein and amino acid intake supports testosterone production and muscle anabolism

Back to Table of Contents

Featured Videos